fibrin organisation within the pleural cavity results in loculations of fluid that may be penetrated poorly by systemically-administered medications. Tissue plasminogen activator (TPA) converts plasminogen to plasmin, which hydrolyses fibrin. Recombinant TPAs are less immunogenic and associated with a lower rate of treatment complications, with alteplase and TNK the most widely used.